SEOM clinical guidelines on cardiovascular toxicity (2018)

Clin Transl Oncol. 2019 Jan;21(1):94-105. doi: 10.1007/s12094-018-02017-3. Epub 2019 Jan 9.

Abstract

One of the most common side effects of cancer treatment is cardiovascular disease, which substantially impacts long-term survivor's prognosis. Cardiotoxicity can be related with either a direct side effect of antitumor therapies or an accelerated development of cardiovascular diseases in the presence of preexisting risk factors. Even though it is widely recognized as an alarming clinical problem, scientific evidence is scarce in the management of these complications in cancer patients. Consequently, current recommendations are based on expert consensus. This Guideline represents SEOM's ongoing commitment to progressing and improving supportive care for cancer patients.

Keywords: Cancer; Cardiotoxicity; Chemotherapy; Early detection; Risk assessment.

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Cardiotonic Agents / therapeutic use*
  • Cardiotoxicity / diagnosis
  • Cardiotoxicity / etiology
  • Cardiotoxicity / prevention & control*
  • Cardiovascular Diseases / chemically induced
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / prevention & control*
  • Clinical Trials as Topic
  • Disease Management
  • Humans
  • Neoplasms / drug therapy*
  • Practice Guidelines as Topic / standards*
  • Prognosis
  • Societies, Medical

Substances

  • Antineoplastic Agents
  • Cardiotonic Agents